Dynamic quotes: Off
|
Company Description (as filed with the SEC)
Albany Molecular Research, Inc. (the “Company,” “AMRI”, “we,” “us,” and “our”), a Delaware corporation incorporated on June 20, 1991, is a global contract research and manufacturing organization providing customers fully integrated drug discovery, development, and manufacturing services. AMRI supplies a broad range of services and technologies that support the discovery and development of pharmaceutical products and the manufacturing of Active Pharmaceutical Ingredients (“API”) and drug product for existing and experimental new drugs. With locations in the United States, Europe, and Asia, AMRI maintains geographic proximity to our customers and flexible cost models. AMRI has also historically leveraged its drug-discovery expertise to execute on several internal drug discovery programs, which have progressed to the development candidate stage and in some cases into Phase I clinical development. ... More ...
Analyst Info |
|
| Annual EPS Est: | $0.25 |
| Quarterly EPS Est: | 0.11 |
| PEG Ratio: | .03 |
|
Mean Recommendation: View Summary / View All |
0 |
Data is provided by Zacks Investment Research

